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 Nrf2 pathway modulates Substance P induced human mast cell activation and 1 
degranulation in the hair follicle 2 
Capsule summary: Activation of Nrf2 in human mast cells exposed to Substance P induced 3 
oxidative stress suppresses pro-inflammatory gene transcription, activation and 4 
degranulation.  5 
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To the Editor: 12 
Mast cells (MCs), are immune cells distributed throughout various tissues that respond to 13 
allergic and inflammatory reactions1 . The neuropeptide Substance P (SP) is a stimulus that 14 
generates damaging reactive oxygen species (ROS) via activation of neurokinin-1 (NRK-1) 15 
and G-protein couple receptor MRGPRX2 and causes MC degranulation2,3. This SP-induced 16 
MC degranulation can result in the excessive accumulation of ROS causing inhibition of hair 17 
growth3(S1-S3).  18 
Importantly, IgE-induced MCs degranulation in the RBL-2H3 cell line can be suppressed by 19 
activation of the Nrf2 (nuclear factor (erythroid-derived 2)-like 2) target gene, heme-20 
oxygenase 1 (HO-1)4, therefore we were interested in the role of Nrf2 in the SP-mediated 21 
activation of primary human MCs in situ and in vitro. Nrf2 controls cellular responses to 22 
oxidative stress by transcriptional regulation of antioxidant genes(S4).  The connective tissue 23 
sheath (CTS) of human HFs contains MCs, which allows investigation of human MC 24 
phenotype and activities under physiologically relevant conditions ex vivo5(S5). We examined 25 
whether the Nrf2 transcriptional pathway can be activated within human MCs and whether 26 
this modulates SP-induced MC degranulation and secretory activity in vitro and in situ. 27 
Nrf2/Mast Cell Tryptase (MCT) double immuno-staining was performed on human scalp HF 28 
sections. Intramesenchymal Nrf2 protein expression in the CTS was low (Figure 1A) and 29 
treatment with SFN did not increase Nrf2/MCT double+ cell number (Figure 1B). Recently 30 
we demonstrated Nrf2-mediated upregulation of HO-1 in human HF CTS by the Nrf2 31 
activator, Sulforaphane (SFN)6. Therefore, isolated human HFs were pre-treated with SFN 32 
for 24 hrs followed by SP stimulation for 4 hrs to activate native CTS MCs ex vivo. This 33 
significantly increased the number of HO-1/MCT double-positive MCs in the CTS (Figure 34 
1C-D). Importantly, stimulation with SP did not increase the number of MCs, as it has been 35 
shown in previous report(S1). 36 
Next, Nrf2 activation by SFN, in primary human peripheral blood-derived cultured MCs 37 
(PBDMCs) was investigated. An increase in Nrf2 phosphorylation is observed following 38 
activation and is associated with increased nuclear translocation and transcriptional 39 
activity(S4). Using immunohistochemistry, Nrf2 displayed both cytoplasmic and nuclear 40 
localisations under basal conditions, whilst SFN treatment increasing nuclear Nrf2 41 
accumulation (Figure 1E-F). However, in LAD2 Nrf2 localisation was only cytoplasmic in 42 
vehicle and SFN treated conditions (Supplementary Figure 1). 43 
We asked whether the expression of Nrf2 target genes and pro-inflammatory MC genes is 44 
modulated by SFN 24 hrs or SP 6 hrs in PBDMCs. A significant increase in the mRNA 45 
expression of the Nrf2 target genes HO-1 and NADP(H) dehydrogenase-quinone 1 (NQO1) 46 
(Figure 1G-H) was observed following SFN treatment. SP induced significant mRNA 47 
transcription of the pro-inflammatory cytokine IL-1β (Figure 1I), followed by reduction prior 48 
SFN treatment. However, we did not observe the same transcriptional effect of the MC 49 
activation marker CD69(S8) or TNF-α (Supplementary Figure 2A-B). In LAD2 similar effect 50 
was detected (Supplementary Figure 3).  51 
Furthermore, we investigated whether Nrf2 activation could modulate SP-induced MC 52 
degranulation. In LAD2 cells, SP triggered high surface expression of MC degranulation 53 
markers CD107a and CD63 by nearly 70%, while SFN alone or prior SP 1 had no effect 54 
(Supplementary Figures 4A-B). We also measured well-established β-hexominidase release, 55 
yet no effect was detected (Supplementary Figure 4C). Therefore, PBDMCs were 56 
investigated next and while their surface expression of CD63 and CD107a after SP 57 
stimulation was approximately 30%, pre-treatment of PBMCs with SFN prior SP treatment 58 
significantly reduced SP-stimulated of both markers (Figure 2A-C). Furthermore, SP induced 59 
β-hexominidase release, whilst pre-treatment with SFN reduced β-hexominidase levels 60 
(Figure 2D). Pre-treatment with SFN for 24 hrs did not show this protective effect 61 
(Supplementary Figure 5A-B). Importantly, the inhibitory effect of SFN varies in intensity 62 
between PBDMCs cultures. Previously, Matsushima et al. (2009) determined that 63 
upregulation of HO-1 by the Nrf2 activator quercetin occurs rapidly, resulting in suppression 64 
of degranulation in RBL-2H3 cells. It may well be that the 1 hr stimulation with SFN used in 65 
this study stimulates a similarly rapid increase in HO-1 expression and enzymatic activity to 66 
suppress SP induced degranulation4. 67 
MCs are major source of Prostaglandin (PGE2) and Prostaglandin D2 (PGD2) production
7 and 68 
the release can occur very quickly upon stimulation(S9). We investigated Nrf2 activation by 69 
SFN for 1 hr (Figure 2E-F) or 24 hrs (Supplementary Figure 6A-B) impact on the 1hr SP-70 
induced secretion for these PGs into the PBDMCs supernatant by ELISA. A significant 71 
increase in PGD2 release occurred following SP treatment, whereas pre-treatment with SFN 72 
prior to SP reduced this, though this did not reach the level of significance (Figure 2E). PGE2 73 
release was largely unaffected by either SFN pre-treatment or SP exposure (Figure 2F). 74 
However, we found that SFN and SP treatment does not disturb the levels of prostaglandin 75 
D2 synthase (PTGDs) and prostaglandin E2 synthase (PTGEs) at mRNA levels 76 
(Supplementary Figure 6C-D).  77 
Finally, we asked whether the SP-induced degranulation of native human skin MCs can be 78 
suppressed by SFN ex vivo, using toluidine blue histochemistry. Results showed significant 79 
SP-stimulated MC degranulation within the CTS, whilst SFN pre-treatment reduced not only 80 
SP-stimulated degranulation but also the SP-induced increase in the total number of toluidine 81 
blue+ human skin MCs (Figure 2G-I).  82 
Our results provide the first evidence that human MCs exhibit substantial Nrf2 activity, 83 
which can effectively supress MC activation and degranulation induced by the neuropeptide 84 
SP. Importantly, PGD2 levels are increased in balding scalp HFs, whilst PGE2 levels are 85 
decreased (S10-S11), therefore the intrafollicular balance between PGD2 and PGE2 has to be 86 
controlled for optimal hair growth8(S12). Increased MC numbers/degranulation have been 87 
reported in androgenic alopecia (AGA)8, and in the most common inflammatory hair growth 88 
disorder, alopecia areata (AA), density, degranulation and proliferation of perifollicular MCs 89 
are also increased9 (S13-14). The therapeutic targeting of Nrf2 in perifollicular MCs may be of 90 
particular interest in the future management of both AGA and AA.  91 
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Figure 1: Nrf2 activity within human MCs. (A) Nrf2 and MCT immunofluorescent 110 
staining in isolated human HFs. MCT+ cells (green) showed low expression of Nrf2 111 
immunofluorescence (red) with infrequent Nrf2/MCT double positive immunofluorescence. 112 
(B) The number of Nrf2/MCT double+ cells did not increase after 2 hr and 4hrs (the graph 113 
presents combined 2hrs and 4hrs treatment of SFN) (C-D) Treatment with SFN and SP 114 
significantly increased expression of MCT/HO-1 double+ cells. MCT (purple) detected in the 115 
CTS and HO-1 (red) activity was found in the HF epithelium and vasculature of CTS. (n=3; 116 
data are mean ± SEM; One-Way ANOVA; Significance indicated by *P<0.05;**P<0.01; 117 
***P<0.001). (E-F) Expression of phoshoprylated nuclear Nrf2 (red) in human primary MCs 118 
is increased after treatment with SFN (n=3; ±SD). (G) HO-1, (H) NQO1, (I) IL-1β, (J) CD69 119 
in PBDMCs were measured by qRT-PCR and data reported as fold changes in normalized 120 
expression (n=3; data are mean ±SEM; RM-One Way ANOVA; Significance indicated by 121 
*P<0.05; **P<0.01; ***P<0.001). 122 
 123 
Figure 2: Stimulation with SP induces MC degranulation and upregulates secretion of 124 
mediators. (A) Gating strategy identifying expression of CD107a and CD63 in PBDMCs. 125 
(B-C) Decrease of CD63 and CD107a PBDMCs after pre-treatment with SFN (D) Pre-126 
treatment with SP suppressed SP induced β-hexominidase release (n=7; data are mean 127 
±SEM; paired t-test; Significance indicated by *P<0.05) (E-F) Secretion of lipid-derivatives 128 
after treatment with SFN and SP (n=4-5; data are mean ±SEM; One-Way ANOVA; 129 
Significance indicated by *P<0.05) (G-I) Toluidine blue staining indicated MCs 130 
degranulation and number within CTS of human HFs (n=3; data are mean ±SEM; One-Way 131 
ANOVA; Significance indicated by *P<0.05;**P<0.01; ***P<0.001). 132 
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Methods 212 
Human HF collection 213 
Occipital scalp hair follicles (HFs) from male hair transplant surgeries were delivered from 214 
the Farjo Medical Centre (Manchester, UK). Male patients that undergone hair transplant 215 
surgery were suffering from AGA, but the occipital scalp HFs are androgen-insensitive and 216 
not affected by AGA, therefore suitable for the experimental procedures. The tissue was 217 
collected after informed patient consent according to the ‘Declaration of Helsinki Principles’ 218 
together with institutional approval ethics from the University of Manchester. 219 
Human HF organ culture 220 
Isolated full-length scalp HFs in anagen VI were cultured in William’s E media (Gibco ®, 221 
Leicestershire, UK) supplemented with 2 mM of L-Glutamine (Invitrogen, Paisley, UK), 222 
10ng/mL hydrocortisone (Sigma-Aldrich ®, UK), 1 μg penicilin/streptomycin antibiotic 223 
mixture (Gibco®, Leicestershire, UK), insulin-transferin-selenium (Life technologies, 224 
Paisley, UK) at 370C 5 % CO2 incubator
(S15-S16). Nrf2 activation was performed using 20 μM 225 
of SFN (Sigma-Aldrich ®, UK) for 2 hours, 4 hours and 24 hours and 2 μM of SP (Milipore, 226 
Nottingham, UK) for 4 hours.  227 
Immunofluorescence microscopy and immunohistochemistry 228 
Double staining of Nrf2/MCT was performed using PerkinElmer TSA plus Kit (PerkinElmer, 229 
UK). Cryosections (6 μm) were fixed in 4 % PFA followed by permeabelisation in 0.1 % 230 
Triton X. The blocking was performed using 3 % H2O2 (Sigma-Aldrich ®, UK) followed by 231 
washes with TNT buffer. Additional blocking was done using TNB and primary Nrf2 232 
antibody (Abcam 31163, Cambridge, UK) was left overnight at 40C before incubation with 233 
HRP goat-anti-rabbit (Life Technologies, Paisley, UK). Additional blocking was done using 234 
Bloxall (Vector, Peterborough, UK) before addition of secondary MCT antibody (Abcam 235 
2378, Cambridge, UK).  236 
PBDMCs were dried at room temperature after stimulation with SFN (5 μM) for 2 hrs and 237 
stained for Nrf2 phospho-S40 (Abcam76026, Cambridge, UK). Washes were done using TBS 238 
+ 0.1 % Tween 20. The blocking was performed using normal goat serum (NGS) 10 % and 239 
primary antibody was diluted 1:100 followed by overnight incubation. Subsequently, 240 
secondary antibody AF594 (goat anti-rabbit) (Life Technologies, Paisley, UK) 1:200 was 241 
added for one hour, followed by washes and counterstain with DAPI. 242 
 MCT/HO-1 double-immunostaining was performed using Vector Immpress kit (Vector, 243 
Peterborough, UK). Slides were blocked using Bloxall followed by incubation with 2.5 % 244 
normal horse serum and primary HO-1 antibody (Sigma HPA000635, Sigma-Aldrich ®, 245 
UK). Washes were performed using PBS and secondary MCT antibody (Abcam 2378, 246 
Cambridge, UK) was used. Toluidine blue histochemistry (Tol) was performed by fixing 247 
slides in acetone, followed by washes in water before staining in Tol blue working solution 248 
for 3 minutes. The analysis of immunostaining was performed using a Biozero-8000 249 
microscope (Keyence, Milton Keynes, UK) and staining analysis was quantified by ImageJ 250 
software (NIH).  Degranulated MCs were identified by quantifying 5 or more extracellular 251 
metachromatic granules in the direct vicinity of a clearly identifiable perifollicular MCs5(S5). 252 
Primary human peripheral blood-derived cultured MCs (PBDMCs) 253 
Human peripheral blood was obtained from a blood bank in Manchester. Mononuclear cells 254 
were obtained and CD117+ progenitor cells were isolated by positive selection of FcRI 255 
block/CD117+ (Miltenyi Biotec GmbH, Surrey, UK) by magnetic cell sorting(S17). For the 256 
first four weeks cells were cultured in StemSpam medium supplement with 1 % 257 
penicilin/streptomycin (Invitrogen, Paisley, UK), 50 ng/ml IL-6 (Peprotech, UK), 10 ng/mL 258 
IL-3 (Peprotech, UK), 100 ng/mL Stem Cell factor (Peprotech, UK) and 10 μg/mL of LDL 259 
(StemCell Technologies, Cambridge, UK). After four weeks cells were cultured in IMDM 260 
medium (Thermofisher, Paisley, UK) supplemented with 50 μM 2b-mercaptoethanol (Sigma- 261 
Aldrich ®, UK), 0.5 % BSA (Life Technologies, Paisley, UK), 1 % insulin – transferrin – 262 
selenium (Life Technologies, Paisley, UK), 1 % penicilin/steptomycin (Invitrogen, Paisley, 263 
UK), 50 ng/mL IL-6 (Peprotech,UK) and 100 ng/mL stem cell factor (rhSCF) (Peprotech, 264 
UK). Cell viability and maturity after eight weeks was measured using fluorochrome-265 
conjugated antibodies FcεRI (Biolegend, London, UK) and CD117 (Biolegend, London, UK) 266 
by FlowCytometry.  267 
LAD2 cell line culture 268 
Laboratory of Allergic Diseases 2 (LAD2) cells (kindly supplied by the NIAID, USA: Arnold 269 
S. Kirshenbaum, and Dean D. Metcalfe) were cultured in StemPro-34 serum-free medium 270 
(Invitrogen, Paisley, UK) supplemented with 100 U/mL penicilin/streptomycin (Invitrogen, 271 
Paisley, UK), 100 U/mL glutamine (Invitrogen, Paisley, UK) and 100 ng/mL rhSCF 272 
(Peprotech, UK)(S7). 273 
MC degranulation and activity assay 274 
MC activity and degranulation was measured using flow cytometry. Briefly, LAD2 cells and 275 
PBDMCs (1.5 x 105) were seeded in 96-well plate and stimulated with 5 μM SFN (Sigma-276 
Aldrich ®, UK) for 1 hr or 24 hrs followed by stimulation with 5μM SP (Milipore, 277 
Nottingham, UK) for 1 hr. Subsequently, cells were resuspended in FACS-buffer (2% 278 
newborn calf serum, 0.1% NaN3, 2mM EDTA in PBS) and stained with fluorochrome-279 
conjugated antibodies CD63 and CD69 (Biolegend, London,UK) for 30 min at 40C followed 280 
by wash with  Live/Dead® Fixable Blue dead cell stain kit for UV excitation 281 
(LifeTechnologies, Paisley, UK). Samples were analysed with a LSR II or Fortessa (BD 282 
Biosciences, Oxford, UK). 283 
 284 
 285 
 286 
 287 
RNA isolation and RT-PCR 288 
LAD2 cells or PBDMCs (1.5 x 105) were treated with 5 μM SFN for 24 hrs followed by 289 
stimulation with 5 μM SP for 6 hrs. Total RNA was extracted with an RNeasy Micro kit 290 
(Qiagen, Manchester,UK) according to the manufacturer’s instructions. Complimentary DNA 291 
(cDNA) was reverse transcribed using Tetro®cDNA synthesis kit (Bioline,UK). Quantitative 292 
– PCR was performed using StepOne™ real time PCR system (Applied Biosystems, 293 
Warrington,UK) using Taqman® fast advance master mix and probes (Applied Biosystems, 294 
Warrington,UK). The following probes from AppliedBiosystems were HMOX1 295 
(Hs01110250_m1), NQO1 (Hs02512143_s1), CD69 (Hs00934033_m1) and most important 296 
pro-inflammatory mediator in skin disorders IL-1β (Hs00174097_m1). In addition, PTGDS 297 
(Hs00168748_m1) and PTGES (Hs00610420_m1) were used. Samples were run using the 298 
StepOne Plus™ Real-Time PCR system and associated software (Applied Biosystems, 299 
Warrington UK), relative expression was quantified against the housekeeping gene PPIA 300 
(Hs04194521_s1). 301 
MCs mediators release assay 302 
PBDMCs (1 x 105) were cultured with 5 μM SFN for 1 hr and 24 hrs followed by stimulation 303 
with 5 μM SP for 1 hr. Secretion of PGD2 and PGE2 were measured according to the 304 
manufacturer’s instructions (CaymanChemical, Cambridge,UK). 305 
50 µL (25000 cells) from the LAD2 cell or PBDMC cultures were taken and centrifuged to 306 
separate the supernatant and cell pellet. Cell pellets were lysed in 50 µL media culture 1% 307 
Triton X-100. β-hexosaminidase was measured in supernatant as well as in the cell pellet by 308 
adding 100 µL β-hexosaminidase substrate, 10 mM p-nitrophenyl N-acetyl-beta-D-309 
glucosamine (Sigma-Aldrich) in 0.1M Na2HPO4 buffer (pH4.5) for 2h at 37°C, 5% CO2. The 310 
reaction was stopped by adding 100 µL of 0.2M glycine buffer (pH10).  Optical density was 311 
measured at 405 nm. hMC degranulation was assessed as % release of total β-hexosaminidase. 312 
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